Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Florence Ader and Karine Lacombe.
Florence Ader
Connection Strength
0.584
Karine Lacombe
  1. An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-ß-1a and hydroxychloroquine in hospitalized patients with COVID-19. Clin Microbiol Infect. 2021 Dec; 27(12):1826-1837.
    View in: PubMed
    Score: 0.237
  2. Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19. Blood. 2020 11 12; 136(20):2290-2295.
    View in: PubMed
    Score: 0.228
  3. Pharmacokinetics and Safety of XAV-19, a Swine Glyco-humanized Polyclonal Anti-SARS-CoV-2 Antibody, for COVID-19-Related Moderate Pneumonia: a Randomized, Double-Blind, Placebo-Controlled, Phase IIa Study. Antimicrob Agents Chemother. 2021 08 17; 65(9):e0123721.
    View in: PubMed
    Score: 0.060
  4. Evaluation of the safety and efficacy of XAV-19 in patients with COVID-19-induced moderate pneumonia: study protocol for a randomized, double-blinded, placebo-controlled phase 2 (2a and 2b) trial. Trials. 2021 Mar 09; 22(1):199.
    View in: PubMed
    Score: 0.058
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.